This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
How Are Biotech ETFs Reacting to Q3 Earnings Releases?
by Sanghamitra Saha
Biotech earnings have come in upbeat in the third quarter.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Markets Up on Election Day; DIS, AFRM Report, Sell Off
by Mark Vickery
Perhaps well have a clear picture of midterm results prior to Thursday morning's CPI report, or perhaps we won't.
Ligand (LGND) Beats on Q3 Earnings, Lags Sales, Ups '22 Outlook
by Zacks Equity Research
Ligand (LGND) reports mixed third-quarter 2022 numbers, beating sales estimates but missing out on earnings. Share price rises as management lifts financial guidance for the year.
Amgen (AMGN) Beats on Q3 Earnings & Sales, Tweaks 2022 View
by Zacks Equity Research
Amgen (AMGN) beats Q3 estimates for earnings and sales. It tightens previously issued revenue and adjusted earnings guidance ranges.
Amgen (AMGN) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 6.09% and 1.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q3 Earnings on Nov 3: AMGN, REGN & More
by Kinjel Shah
Let us look at five drug and biotech companies, AMGN, REGN, ZTS, and MRNA, which are gearing up for their earnings release.
Pfizer (PFE) Beats on Q3 Earnings, Ups COVID Jab Sales View
by Zacks Equity Research
Pfizer (PFE) beats estimates for Q3 earnings and sales. It ups its sales and earnings view despite a decline in COVID-19 vaccine sales in Q3. Stock up in pre-market trading
Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Tango Therapeutics, Inc. (TNGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Take the Zacks Approach to Beat the Market: Caterpillar, Amgen, Inventiva in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
AbbVie (ABBV) Beats on Q3 Earnings, Lags Sales, Narrows '22 View
by Zacks Equity Research
AbbVie's earnings (ABBV) beat estimates for third-quarter 2022, while sales miss the same. Shares drop in pre-market trading after it narrows down its full-year earnings guidance.
Earnings Preview: Amgen (AMGN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Gilead Sciences Stock Climb After Q3 Earnings?
by Shaun Pruitt
Big Pharma will close out this week's earnings reports, with Gilead Sciences (GILD) set to give its Q3 results on October 27. With GILD edging towards its 52-week highs, investors will want to see if earnings can support a continued rally in its stock.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $251.94, marking a +1.81% move from the previous day.
Amgen (AMGN) Stock Moves -0.3%: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $247.45, marking a -0.3% move from the previous day.
Do Options Traders Know Something About Amgen (AMGN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Amgen (AMGN) stock based on the movements in the options market lately.
Amgen (AMGN) Stock Moves -0.13%: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $251.34, moving -0.13% from the previous trading session.
Strength Seen in Amgen (AMGN): Can Its 5.7% Jump Turn into More Strength?
by Zacks Equity Research
Amgen (AMGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Amgen (AMGN) Crossed Above the 200-Day Moving Average: What That Means for Investors
by Zacks Equity Research
When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?
Amgen (AMGN) Recently Broke Out Above the 50-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
by Zacks Equity Research
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Stock Market News for Oct 12, 2022
by Zacks Equity Research
Wall Street closed mixed on Tuesday after a choppy session.
The Zacks Analyst Blog Highlights Chevron, Amgen, HSBC, CVS Health and S&P Global
by Zacks Equity Research
Chevron, Amgen, HSBC, CVS Health and S&P Global are included in this Analyst Blog.